Company / Profit Margin
Lineage Cell Therapeutics, Inc. Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-436.5%
FY2025
5-year range
-1130.8% / -195.9%
FY2021-FY2025
Trend
-122.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin has fluctuated over the past 10 years, ranging from -1130.8% in FY2021 to -195.9% in FY2024.
Based on SEC 10-K filings.
-436.5% in FY2025 with a 5-year CAGR of -103.4%.
Declined from -240.2% to -436.5% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- +554.5pp
- 5-Year Change
- -103.4pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, profit margin decreased 122.8% year-over-year.
- Peak profit margin was recorded in FY2024.
- Lowest profit margin in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -436.5% | -122.8% |
| FY2024 | -195.9% | +18.4% |
| FY2023 | -240.2% | +75.8% |
| FY2022 | -991.0% | +12.4% |
| FY2021 | -1130.8% | -239.5% |
| FY2020 | -333.1% | +63.9% |
| FY2019 | -922.0% | -59.6% |
| FY2018 | -577.7% | +13.5% |
| FY2017 | -667.9% | +3.8% |
| FY2016 | -694.4% | +29.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026